Annual FCF
-$322.28 M
-$107.43 M-50.00%
31 December 2023
Summary:
Travere Therapeutics annual free cash flow is currently -$322.28 million, with the most recent change of -$107.43 million (-50.00%) on 31 December 2023. During the last 3 years, it has fallen by -$159.69 million (-98.22%).TVTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$50.70 M
+$66.54 M+56.75%
30 September 2024
Summary:
Travere Therapeutics quarterly free cash flow is currently -$50.70 million, with the most recent change of +$66.54 million (+56.75%) on 30 September 2024. Over the past year, it has increased by +$13.36 million (+20.86%). TVTX quarterly FCF is now -289.96% below its all-time high of $26.69 million, reached on 30 September 2021.TVTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$369.41 M
+$13.36 M+3.49%
30 September 2024
Summary:
Travere Therapeutics TTM free cash flow is currently -$369.41 million, with the most recent change of +$13.36 million (+3.49%) on 30 September 2024. Over the past year, it has dropped by -$64.30 million (-21.07%).TVTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TVTX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -50.0% | +20.9% | -21.1% |
| 3 y3 years | -98.2% | -290.0% | -196.4% |
| 5 y5 years | -621.6% | -176.5% | -407.9% |
TVTX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -727.6% | at low | -290.0% | +59.6% | -848.6% | +3.5% |
| 5 y | 5 years | -727.6% | at low | -290.0% | +59.6% | -848.6% | +3.5% |
| alltime | all time | <-9999.0% | at low | -290.0% | +59.6% | <-9999.0% | +3.5% |
Travere Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$50.70 M(-56.8%) | -$369.41 M(-3.5%) |
| June 2024 | - | -$117.24 M(-6.6%) | -$382.77 M(+13.0%) |
| Mar 2024 | - | -$125.47 M(+65.1%) | -$338.67 M(+5.1%) |
| Dec 2023 | -$322.28 M(+50.0%) | -$76.00 M(+18.6%) | -$322.28 M(+5.6%) |
| Sept 2023 | - | -$64.06 M(-12.4%) | -$305.11 M(+5.8%) |
| June 2023 | - | -$73.13 M(-33.0%) | -$288.36 M(+9.5%) |
| Mar 2023 | - | -$109.08 M(+85.4%) | -$263.35 M(+22.6%) |
| Dec 2022 | -$214.85 M(+451.7%) | -$58.84 M(+24.4%) | -$214.85 M(+14.2%) |
| Sept 2022 | - | -$47.31 M(-1.7%) | -$188.09 M(+64.9%) |
| June 2022 | - | -$48.12 M(-20.6%) | -$114.09 M(+78.9%) |
| Mar 2022 | - | -$60.59 M(+88.9%) | -$63.79 M(+63.8%) |
| Dec 2021 | -$38.94 M(-76.0%) | -$32.08 M(-220.2%) | -$38.94 M(-68.7%) |
| Sept 2021 | - | $26.69 M(+1119.2%) | -$124.62 M(-17.7%) |
| June 2021 | - | $2.19 M(-106.1%) | -$151.49 M(-7.9%) |
| Mar 2021 | - | -$35.74 M(-69.6%) | -$164.56 M(+1.2%) |
| Dec 2020 | -$162.59 M(+120.4%) | -$117.75 M(>+9900.0%) | -$162.59 M(+205.0%) |
| Sept 2020 | - | -$180.00 K(-98.3%) | -$53.31 M(-25.4%) |
| June 2020 | - | -$10.89 M(-67.8%) | -$71.47 M(-14.0%) |
| Mar 2020 | - | -$33.77 M(+298.6%) | -$83.08 M(+12.6%) |
| Dec 2019 | -$73.78 M(+65.2%) | -$8.47 M(-53.8%) | -$73.78 M(+1.4%) |
| Sept 2019 | - | -$18.34 M(-18.5%) | -$72.74 M(+17.0%) |
| June 2019 | - | -$22.50 M(-8.1%) | -$62.14 M(+34.7%) |
| Mar 2019 | - | -$24.47 M(+229.3%) | -$46.14 M(+3.3%) |
| Dec 2018 | -$44.66 M(+576.0%) | -$7.43 M(-4.0%) | -$44.66 M(+8.9%) |
| Sept 2018 | - | -$7.74 M(+19.2%) | -$41.02 M(+33.1%) |
| June 2018 | - | -$6.49 M(-71.8%) | -$30.82 M(+40.9%) |
| Mar 2018 | - | -$22.99 M(+506.0%) | -$21.87 M(+231.1%) |
| Dec 2017 | -$6.61 M | -$3.79 M(-254.0%) | -$6.61 M(-57.5%) |
| Sept 2017 | - | $2.46 M(+0.7%) | -$15.54 M(-3.8%) |
| June 2017 | - | $2.45 M(-131.7%) | -$16.16 M(-4.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | -$7.72 M(-39.3%) | -$16.92 M(+10.1%) |
| Dec 2016 | -$15.37 M(+82.5%) | -$12.72 M(-791.1%) | -$15.37 M(+94.1%) |
| Sept 2016 | - | $1.84 M(+9.3%) | -$7.92 M(-32.9%) |
| June 2016 | - | $1.68 M(-127.3%) | -$11.80 M(+68.1%) |
| Mar 2016 | - | -$6.17 M(+16.9%) | -$7.02 M(-16.6%) |
| Dec 2015 | -$8.42 M(-83.1%) | -$5.28 M(+158.5%) | -$8.42 M(-31.7%) |
| Sept 2015 | - | -$2.04 M(-131.6%) | -$12.32 M(-52.5%) |
| June 2015 | - | $6.46 M(-185.4%) | -$25.94 M(-45.2%) |
| Mar 2015 | - | -$7.57 M(-17.5%) | -$47.35 M(-5.0%) |
| Dec 2014 | -$49.81 M(+115.3%) | -$9.18 M(-41.4%) | -$49.81 M(-8.3%) |
| Sept 2014 | - | -$15.66 M(+4.8%) | -$54.31 M(+31.4%) |
| June 2014 | - | -$14.95 M(+49.0%) | -$41.32 M(+44.5%) |
| Mar 2014 | - | -$10.03 M(-26.6%) | -$28.59 M(+23.5%) |
| Dec 2013 | -$23.14 M(+488.8%) | -$13.67 M(+412.3%) | -$23.14 M(+144.3%) |
| Sept 2013 | - | -$2.67 M(+20.3%) | -$9.47 M(+39.2%) |
| June 2013 | - | -$2.22 M(-51.7%) | -$6.80 M(+48.3%) |
| Mar 2013 | - | -$4.59 M(<-9900.0%) | -$4.59 M(<-9900.0%) |
| Dec 2012 | -$3.93 M(<-9900.0%) | - | - |
| Nov 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Aug 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Feb 2012 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Feb 2012 | $0.00(-100.0%) | - | - |
| Nov 2011 | - | $0.00(0.0%) | -$600.00(-14.3%) |
| Aug 2011 | - | $0.00(0.0%) | -$700.00(0.0%) |
| May 2011 | - | $0.00(-100.0%) | -$700.00(0.0%) |
| Feb 2011 | -$700.00 | -$600.00(+500.0%) | -$700.00(+600.0%) |
| Nov 2010 | - | -$100.00(<-9900.0%) | -$100.00(<-9900.0%) |
| Aug 2010 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2010 | - | $0.00 | $0.00 |
FAQ
- What is Travere Therapeutics annual free cash flow?
- What is the all time high annual FCF for Travere Therapeutics?
- What is Travere Therapeutics annual FCF year-on-year change?
- What is Travere Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Travere Therapeutics?
- What is Travere Therapeutics quarterly FCF year-on-year change?
- What is Travere Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Travere Therapeutics?
- What is Travere Therapeutics TTM FCF year-on-year change?
What is Travere Therapeutics annual free cash flow?
The current annual FCF of TVTX is -$322.28 M
What is the all time high annual FCF for Travere Therapeutics?
Travere Therapeutics all-time high annual free cash flow is $0.00
What is Travere Therapeutics annual FCF year-on-year change?
Over the past year, TVTX annual free cash flow has changed by -$107.43 M (-50.00%)
What is Travere Therapeutics quarterly free cash flow?
The current quarterly FCF of TVTX is -$50.70 M
What is the all time high quarterly FCF for Travere Therapeutics?
Travere Therapeutics all-time high quarterly free cash flow is $26.69 M
What is Travere Therapeutics quarterly FCF year-on-year change?
Over the past year, TVTX quarterly free cash flow has changed by +$13.36 M (+20.86%)
What is Travere Therapeutics TTM free cash flow?
The current TTM FCF of TVTX is -$369.41 M
What is the all time high TTM FCF for Travere Therapeutics?
Travere Therapeutics all-time high TTM free cash flow is $0.00
What is Travere Therapeutics TTM FCF year-on-year change?
Over the past year, TVTX TTM free cash flow has changed by -$64.30 M (-21.07%)